Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 04, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Cumberland Pharmaceuticals Inc.
Entity Central Index Key	0001087294
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		15,710,953

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 35,262,976	$ 45,412,868
Marketable securities	15,610,105	4,672,476
Accounts receivable, net of allowances	6,301,162	8,395,112
Inventories, net	6,661,525	6,737,848
Other current assets	2,987,404	3,466,541
Total current assets	66,823,172	68,684,845
Property and equipment, net	566,907	528,882
Intangible assets, net	21,052,197	21,444,545
Deferred tax assets, net	87,210	87,210
Other assets	2,565,354	2,486,830
Total assets	91,094,840	93,232,312
Current liabilities:
Accounts payable	8,518,879	8,979,929
Other current liabilities	7,770,977	8,714,814
Total current liabilities	16,289,856	17,694,743
Revolving line of credit	12,000,000	9,800,000
Other long-term liabilities	1,930,679	1,815,968
Total liabilities	30,220,535	29,310,711
Shareholders’ equity:
Common stock—no par value; 100,000,000 shares authorized; 15,727,250 and 15,723,075 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	51,755,834	52,410,941
Retained earnings	9,329,983	11,709,222
Total shareholders’ equity	61,085,817	64,120,163
Noncontrolling interests	(211,512)	(198,562)
Total equity	60,874,305	63,921,601
Total liabilities and equity	$ 91,094,840	$ 93,232,312

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	15,727,250	15,723,075
Common stock, shares outstanding (in shares)	15,727,250	15,723,075

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Net revenues	$ 8,587,605	$ 9,636,755
Costs and expenses:
Cost of products sold	1,527,961	1,381,497
Selling and marketing	4,670,511	5,293,020
Research and development	1,874,939	898,363
General and administrative	2,330,281	2,110,233
Amortization	636,135	611,444
Total costs and expenses	11,039,827	10,294,557
Operating income (loss)	(2,452,222)	(657,802)
Interest income	82,494	52,535
Interest expense	(18,302)	(31,715)
Income (loss) before income taxes	(2,388,030)	(636,982)
Income tax (expense) benefit	4,159	656,587
Net income (loss)	(2,392,189)	(1,293,569)
Net loss at subsidiary attributable to noncontrolling interests	(12,950)	(19,123)
Net income (loss) attributable to common shareholders	$ (2,379,239)	$ (1,274,446)
Earnings (loss) per share attributable to common shareholders
- basic (in dollars per share)	$ (0.15)	$ (0.08)
- diluted (in dollars per share)	$ (0.15)	$ (0.08)
Weighted-average shares outstanding
- basic (in shares)	15,689,240	16,042,219
- diluted (in shares)	15,689,240	16,042,219
Comprehensive income (loss) attributable to common shareholders	$ (2,379,239)	$ (1,274,446)
Net loss at subsidiary attributable to noncontrolling interests	12,950	19,123
Total comprehensive income (loss)	$ (2,392,189)	$ (1,293,569)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net income (loss)	$ (2,392,189)	$ (1,293,569)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization expense	692,991	661,485
Deferred tax expense	0	758,112
Share-based compensation	339,209	254,585
Excess tax (benefit) expense derived from exercise of stock options		(92,741)
Noncash interest expense	18,303	26,778
Noncash investment gains	43,338	4,807
Net changes in assets and liabilities affecting operating activities:
Accounts receivable	(2,093,950)	(2,395,348)
Inventories	(76,323)	275,175
Other current assets and other assets	(600,884)	(132,819)
Accounts payable and other current liabilities	(1,254,535)	(1,216,345)
Other long-term liabilities	103,991	92,881
Net cash provided by operating activities	235,589	1,439,371
Cash flows from investing activities:
Additions to property and equipment	(94,881)	(123,945)
Purchases of marketable securities	(15,151,948)	(792,716)
Proceeds from sale of marketable securities	4,257,657	941,087
Additions to intangible assets	(532,954)	(453,961)
Net cash used in investing activities	(11,522,126)	(429,535)
Cash flows from financing activities:
Borrowings on line of credit	12,000,000	0
Repayments on line of credit	(9,800,000)	0
Sales of shares of common stock, net of offering costs	200,909	0
Payments of deferred offering costs	(248,108)	0
Repurchase of common shares	(1,016,156)	(545,924)
Net cash provided by (used in) financing activities	1,136,645	(545,924)
Net increase (decrease) in cash and cash equivalents	(10,149,892)	463,912
Cash and cash equivalents at beginning of period	45,412,868	34,510,330
Cash and cash equivalents at end of period	$ 35,262,976	$ 34,974,242

Condensed Consolidated Statement of Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)	Total	Range values are not currently supported	Range values are not currently supported	Range values are not currently supported
Balance, Beginning of Period at Dec. 31, 2017	$ 63,921,601	$ 52,410,941	$ 11,709,222	$ (198,562)
Balance, Beginning of Period (in shares) at Dec. 31, 2017	15,723,075	15,723,075
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from the sale of common stock, net of offering costs	$ 200,909	$ 200,909
Proceeds from the sale of common stock, net of offering costs (in shares)	30,704	30,704
Share-based compensation	$ 339,209	$ 339,209
Share-based compensation (in shares)		145,550
Repurchase of shares	(1,195,225)	$ (1,195,225)
Repurchase of shares (in shares)		(172,079)
Net loss	(2,392,189)		(2,379,239)	(12,950)
Balance, End of Period at Mar. 31, 2018	$ 60,874,305	$ 51,755,834	$ 9,329,983	$ (211,512)
Balance, End of Period (in shares) at Mar. 31, 2018	15,727,250	15,727,250

Organization and Basis of Presentation	3 Months Ended
Organization and Basis of Presentation	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States. In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2017 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2018, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the “SEC”), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report on Form 10-K”). The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period. Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March 31, 2018 and 2017. Adoption of Revenue Accounting Standard Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. Net Product Revenue Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. Sales Rebates and Discounts The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed. Sales Returns Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other tactor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed. Recent Accounting Guidance Recent Adopted Accounting Pronouncements In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers.” (“ASC 606”) The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. The Company is currently applying the standard in its current practices. In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows. In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows. Recent Accounting Pronouncements - Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables. In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-12, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements and disclosures. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, in which it operates the CET Life Sciences Center. This lease currently expires in April 2023. Accounting Policies: Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory. Operating Segments The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers.

Marketable Securities

3 Months Ended

Mar. 31, 2018

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (“SBA”) loan pools, and corporate bonds. At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time. As of March 31, 2018 and December 31, 2017, the marketable securities are comprised solely of trading securities. Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income (loss).

The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:

Level 1 - Quoted prices for identical instruments in active markets.

Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 - Significant inputs to the valuation model are unobservable.

The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment. The Company has no marketable securities in which the fair value is determined based on Level 3 measurements. The level of management judgment required in evaluating fair value for Level 1 investments is minimal. Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with

similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices). There were no transfers of assets between levels within the fair value hierarchy.

The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:


	March 31, 2018						December 31, 2017
	Level 1		Level 2		Total		Level 1		Level 2		Total

U.S. Treasury notes and bonds	$	6,486,345	$	—	$	6,486,345	$	—	$	—	$	—
U.S. Agency issued mortgage-backed securities – variable rate	$	—	$	1,569,884	$	1,569,884	$	—	$	3,539,102	$	3,539,102
U.S. Agency notes and bonds – fixed rate	—		—		—		—		198,293		198,293
Corporate bonds	—		2,502,977		2,502,977		—		—		—
SBA loan pools – variable rate	—		548,641		548,641		—		935,081		935,081
Short-term cash investments	—		4,502,258		4,502,258		—		—		—
Total fair value of marketable securities	$	6,486,345	$	9,123,760	$	15,610,105	$	—	$	4,672,476	$	4,672,476

Earnings (Loss) Per Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

EARNINGS (LOSS) PER SHARE

The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2018 and 2017:


	Three months ended March 31,
	2018		2017









Numerator:
Net income (loss) attributable to common shareholders	$	(2,379,239)	$	(1,274,446)
Denominator:
Weighted-average shares outstanding – basic	15,689,240		16,042,219
Dilutive effect of other securities	—		—
Weighted-average shares outstanding – diluted	15,689,240		16,042,219

As of March 31, 2018 and 2017, restricted stock awards and options to purchase 247,530 and 237,875 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.

Revenues

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

REVENUES

Product Revenues

The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements. See further discussion in Note 1.

The Company’s net revenues consisted of the following for the three months ended March 31, 2018 and 2017:


	Three months ended March 31,
	2018		2017
Products:
Acetadote	$	1,273,764	$	1,265,440
Omeclamox-Pak	141,392		645,325
Kristalose	3,269,901		2,386,591
Vaprisol	93,890		684,548
Caldolor	1,039,747		813,027
Ethyol	2,256,073		3,666,808
Totect	412,774		—
Other	100,064		175,016
Total net revenues	$	8,587,605	$	9,636,755

Cumberland supplies Perrigo Company (“Perrigo”) with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was $0.8 million and $0.9 million for first quarter of 2018 and 2017, respectively.

Other Revenues

The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.

Inventories

3 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

INVENTORIES

The Company works closely with third parties to manufacture and package finished goods for sale. Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.

The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At March 31, 2018 and December 31, 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.2 million, respectively.

In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at March 31, 2018 and December 31, 2017.

As of March 31, 2018 and December 31, 2017, net inventory consisted of the following:


	March 31, 2018		December 31, 2017
Raw materials and work in process	$	2,642,543	$	3,156,002
Consigned inventory	418,829		249,964
Finished goods	3,600,153		3,331,882
Total	$	6,661,525	$	6,737,848

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“the Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21% (2) eliminating the corporate alternative minimum tax ("AMT") and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation. The SEC staff issued Staff Accounting Bulletin (“SAB”) 118 which provides guidance for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. In connection with our analysis of the impact of the Tax Act, we have a net tax benefit of $0.1 million of March 31, 2018. This net tax benefit consists entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. While the Company does not expect to record further amounts related to the Tax Act, we will continue to evaluate additional guidance as it is released by the Internal Revenue Service and will record additional amounts if needed. The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.

Collaborative Agreements	3 Months Ended
Collaborative Agreements	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
COLLABORATIVE AGREEMENTS	COLLABORATIVE AGREEMENTSCumberland is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or Federal Small Business Administration (SBIR/STTR) grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from private sector investments and grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Matters The Company developed a new formulation of Acetadote (acetylcysteine) Injection as part of the Phase IV commitment in response to a request by the FDA regarding the role of EDTA in the product's formulation. The Company has received several patents from the United States Patent and Trademark Office ("USPTO") since 2012 as well as notices that its Acetadote patents are being challenged on the basis of invalidity or non-infringement by others. During the third quarter of 2015, an arbitrator issued a final award in the Company’s favor, enjoining Mylan Pharma Group Limited and Mylan Teoranta, together with all their affiliates (“Mylan”), from selling, delivering, or giving away any acetylcysteine injectable drug product to another entity or person until April 30, 2018. The arbitration request was filed with the American Arbitration Association for claims against Mylan in connection with agreements which require that Mylan manufacture and supply acetylcysteine drug product, including Acetadote, for us exclusively until April 2016. As the prevailing party, the Company received reimbursement of its attorney’s fees and related costs associated with the arbitration. During the third quarter of 2015, the United States District Court for the Northern District of Illinois, Eastern Division ("District Court") ruled in the Company’s favor in its lawsuit against Mylan for infringement of its U.S. Patent number 8,399,445 (the “445 Acetadote Patent”). The opinion upheld our 445 Acetadote Patent and expressly rejected Mylan's validity challenge. The District Court ruled that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan's Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote. On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the "Appeals Court"). On January 26, 2017, the Appeals Court affirmed the District Court ruling in the Company's favor in its lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court’s ruling upholding Cumberland's 445 Acetadote Patent and expressly rejected Mylan's validity challenge. Additional information on these developments is included in Part 1, Item 3, Legal Proceedings in our Annual Report on Form 10-K for the year ended December 31, 2017.

Organization and Basis of Presentation (Policies)	3 Months Ended
Organization and Basis of Presentation (Policies)	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Guidance	Recent Adopted Accounting Pronouncements In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers.” (“ASC 606”) The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. The Company is currently applying the standard in its current practices. In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows. In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows. Recent Accounting Pronouncements - Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables. In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-12, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements and disclosures. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, in which it operates the CET Life Sciences Center. This lease currently expires in April 2023.
Use of Estimates	Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.
Operating Segments	Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers.

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2018

Investments, Debt and Equity Securities [Abstract]

Fair value of marketable securities, by type

The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:


	March 31, 2018						December 31, 2017
	Level 1		Level 2		Total		Level 1		Level 2		Total

U.S. Treasury notes and bonds	$	6,486,345	$	—	$	6,486,345	$	—	$	—	$	—
U.S. Agency issued mortgage-backed securities – variable rate	$	—	$	1,569,884	$	1,569,884	$	—	$	3,539,102	$	3,539,102
U.S. Agency notes and bonds – fixed rate	—		—		—		—		198,293		198,293
Corporate bonds	—		2,502,977		2,502,977		—		—		—
SBA loan pools – variable rate	—		548,641		548,641		—		935,081		935,081
Short-term cash investments	—		4,502,258		4,502,258		—		—		—
Total fair value of marketable securities	$	6,486,345	$	9,123,760	$	15,610,105	$	—	$	4,672,476	$	4,672,476

Earnings (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Reconciliation of numerator and denominator

The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2018 and 2017:


	Three months ended March 31,
	2018		2017









Numerator:
Net income (loss) attributable to common shareholders	$	(2,379,239)	$	(1,274,446)
Denominator:
Weighted-average shares outstanding – basic	15,689,240		16,042,219
Dilutive effect of other securities	—		—
Weighted-average shares outstanding – diluted	15,689,240		16,042,219

Revenues (Tables)

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2018 and 2017:


	Three months ended March 31,
	2018		2017
Products:
Acetadote	$	1,273,764	$	1,265,440
Omeclamox-Pak	141,392		645,325
Kristalose	3,269,901		2,386,591
Vaprisol	93,890		684,548
Caldolor	1,039,747		813,027
Ethyol	2,256,073		3,666,808
Totect	412,774		—
Other	100,064		175,016
Total net revenues	$	8,587,605	$	9,636,755

Inventories (Tables)

3 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

Inventory

As of March 31, 2018 and December 31, 2017, net inventory consisted of the following:


	March 31, 2018		December 31, 2017
Raw materials and work in process	$	2,642,543	$	3,156,002
Consigned inventory	418,829		249,964
Finished goods	3,600,153		3,331,882
Total	$	6,661,525	$	6,737,848

Organization and Basis of Presentation Organization (Details)	3 Months Ended
	Mar. 31, 2018 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Marketable Securities (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	$ 15,610,105	$ 4,672,476
U.S. Treasury notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	6,486,345	0
U.S. Agency issued mortgage-backed securities – variable rate
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	1,569,884	3,539,102
U.S. Agency notes and bonds – fixed rate
Schedule of Available-for-sale Securities [Line Items]
Marketable securities		198,293
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	2,502,977	0

Schedule of Available-for-sale Securities [Line Items]
Marketable securities	548,641	935,081
Short-term cash investments
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	4,502,258
Level 1
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	6,486,345
Level 1 \| U.S. Treasury notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	6,486,345	0
Level 1 \| U.S. Agency issued mortgage-backed securities – variable rate
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	0	0
Level 1 \| U.S. Agency notes and bonds – fixed rate
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	0	0
Level 1 \| Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	0	0
Level 1 \|
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	0	0
Level 1 \| Short-term cash investments
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	0
Level 2
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	9,123,760	4,672,476
Level 2 \| U.S. Treasury notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	0	0
Level 2 \| U.S. Agency issued mortgage-backed securities – variable rate
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	1,569,884	3,539,102
Level 2 \| U.S. Agency notes and bonds – fixed rate
Schedule of Available-for-sale Securities [Line Items]
Marketable securities		198,293
Level 2 \| Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	2,502,977	0
Level 2 \|
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	548,641	935,081
Level 2 \| Short-term cash investments
Schedule of Available-for-sale Securities [Line Items]
Marketable securities	$ 4,502,258	$ 0

Earnings (Loss) Per Share (Details) - USD ($)	3 Months Ended
Earnings (Loss) Per Share (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Numerator:
Net income (loss) attributable to common shareholders	$ (2,379,239)	$ (1,274,446)
Denominator:
Weighted-average shares outstanding – basic (in shares)	15,689,240	16,042,219
Weighted-average shares outstanding – diluted (in shares)	15,689,240	16,042,219

Earnings (Loss) Per Share - Textual (Details) - shares	3 Months Ended
Earnings (Loss) Per Share - Textual (Details) - shares	Mar. 31, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Common stock available for purchase through restricted stock awards and options (in shares)	247,530	237,875

Revenues (Details) - USD ($)	3 Months Ended
Revenues (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Products [Abstract]
Net revenues	$ 8,587,605	$ 9,636,755
Acetadote
Products [Abstract]
Net revenues	1,273,764	1,265,440
Omeclamox-Pak
Products [Abstract]
Net revenues	141,392	645,325
Kristalose
Products [Abstract]
Net revenues	3,269,901	2,386,591
Vaprisol
Products [Abstract]
Net revenues	93,890	684,548
Caldolor
Products [Abstract]
Net revenues	1,039,747	813,027
Ethyol
Products [Abstract]
Net revenues	2,256,073	3,666,808
Totect
Products [Abstract]
Net revenues	412,774	0
Other
Products [Abstract]
Net revenues	100,064	175,016
Generic Acetadote
Products [Abstract]
Net revenues	$ 800,000	$ 900,000

Inventories (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Inventory
Raw materials and work in process	$ 2,642,543	$ 3,156,002
Consigned inventory	418,829	249,964
Finished goods	3,600,153	3,331,882
Total	$ 6,661,525	$ 6,737,848

Inventories - Textual (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Reserve for potential obsolescence of products	$ 100,000	$ 200,000

Shareholders' Equity and Debt	3 Months Ended
Shareholders' Equity and Debt	Mar. 31, 2018
Equity and Debt [Abstract]
SHAREHOLDERS' EQUITY AND DEBT	SHAREHOLDERS’ EQUITY AND DEBT Share Repurchases The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2016, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. During the three months ended March 31, 2018 and March 31, 2017, the Company repurchased 172,079 shares and 155,150 shares, respectively, of common stock for approximately $1.2 million and $1.0 million, respectively. Share Sales In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the three months ended March 31, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (“ATM”) sales agreement with B. Riley FBR. Restricted Share Grants During the three months ended March 31, 2018, the Company issued 229,205 shares of restricted stock to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss). Debt Agreement On July 31, 2017, the Company entered into a Revolving Credit Loan Agreement with Pinnacle Bank ("Pinnacle Agreement"). The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $12.0 million in borrowings under that agreement at March 31, 2018. The Pinnacle Agreement provides for an aggregate principal amount of up to $20 million and has a three-year term expiring on July 31, 2020. The initial revolving line of credit is up to $12 million with the ability to increase the borrowing amount up to $20 million, upon the satisfaction of certain conditions. The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 3.3% at March 31, 2018). In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. Borrowings under the line of credit are collateralized by substantially all of our assets. Under the Pinnacle Agreement, Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis. The Company achieved compliance with the Funded Debt Ratio covenant as of March 31, 2018 through the utilization of the covenant cure section of the agreement.

Shareholders' Equity and Debt - Shareholders' Equity (Details) - USD ($)	1 Months Ended	3 Months Ended
	Nov. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2013	Apr. 30, 2012	Jan. 31, 2011	May 13, 2010
Shareholders Equity [Abstract]
Repurchase outstanding common shares				$ 10,000,000	$ 10,000,000	$ 10,000,000	$ 10,000,000	$ 10,000,000	$ 10,000,000
Repurchase of shares, value		$ (1,195,225)
Shelf Registration, sale of corporate securities (up to)	$ 100,000,000
Issuance of common stock (in shares)		30,704
Gross proceeds from issuance of common stock		$ 200,909	$ 0
Restricted Stock
Shareholders Equity [Abstract]
Restricted stock granted in period, shares		229,205
Director \| Restricted Stock
Shareholders Equity [Abstract]
Restricted stock awards, vesting period		1 year
Range values are not currently supported
Shareholders Equity [Abstract]
Repurchase of shares (in shares)		172,079	155,150
Repurchase of shares, value		$ (1,195,225)	$ (1,000,000.0)
Issuance of common stock (in shares)		30,704

Shareholders' Equity and Debt - Debt (Details) - USD ($)	Jul. 31, 2017	Mar. 31, 2018	Dec. 31, 2017
Line of Credit Facility [Line Items]
Revolving line of credit		$ 12,000,000	$ 9,800,000
Pinnacle Bank \| Line of Credit \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity upon satisfaction of certain conditions	$ 20,000,000
Expiration period	3 years
Line of credit, maximum borrowing capacity	$ 12,000,000
Line of credit, unused capacity, commitment fee percentage	0.25%
Pinnacle Bank \| Line of Credit \| Revolving Credit Facility \| Minimum
Line of Credit Facility [Line Items]
Interest rate spread	1.75%
Pinnacle Bank \| Line of Credit \| Revolving Credit Facility \| Maximum
Line of Credit Facility [Line Items]
Interest rate spread	2.75%
SunTrust Bank \| Line of Credit \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Effective interest rate		3.30%

Income Taxes - Textual (Details) $ in Millions	Mar. 31, 2018 USD ($)
Income Tax Disclosure [Abstract]
Net tax benefit	$ 0.1